Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin in Central Neuropathic Pain After Spinal Cord Injury
jRCT2080224584Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mirogabalin in central neuropathic pain (CNP) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Weekly Average Daily Pain Score (ADPS). Started Mar 2019; status: completed.
02
Drugs
mirogabalin
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on jRCT2080224584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224584.